Simulations Plus

The company has produced specific proprietary software products, such as: • GastroPlus™, a physiologically-based simulation tool that predicts the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions for compounds administered through intravenous, oral, ocular, or pulmonary routes. • ADMET Predictor™, an ADME-Tox property prediction and model building application. • MedChem Studio™, a multi-purpose cheminformatics platform used for advanced data mining and de novo molecule design. • DDDPlus™, a simulation program for formulation scientists that predicts the in vitro disintegration and dissolution of solid dosage forms under different experimental conditions. • MedChem Designer™, a FREE chemical sketching product that combines innovative molecule drawing features with fast and accurate ADMET property predictions from ADMET Predictor. As of January 2014, 19 of the top 20 pharmaceutical companies, along with most major regulatory agencies, license the company's software.
Lancaster, US
57 (est)
Simulations Plus was founded in 1996 and is headquartered in Lancaster, US

Simulations Plus Locations

Lancaster, US
Buffalo, US

Simulations Plus Metrics

Simulations Plus Summary

Market capitalization

$173 M

Closing share price

Simulations Plus's current market capitalization is $173 M.

Simulations Plus Market Value History

We estimate that Simulations Plus's current employees are approximately 9% female and 91% male.

Simulations Plus Online Presence

Simulations Plus News

Simulations Plus Company Life

You may also be interested in